Navigation Links
The Number of Biotechnology Companies has Only Decreased by 10% Despite the Crisis
Date:9/30/2010

The Number of Biotechnology Companies has Only Decreased by 10% Despite the... -- PAMPLONA, Spain, September 30, 2010 /PRNewswire/ --


Advanced Search Search

  
Close
  1. Send a release
  2. Member sign in
  3. Become a member
  4. For journalists
  5. Global sites
PR Newswire: news distribution, targeting and monitoring
  1. Products & Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire
Biotechnology, Health Care & Hospitals, Medical Pharmaceuticals, Surveys, Polls and Research Click to view news release full screen  

The Number of Biotechnology Companies has Only Decreased by 10% Despite the Crisis

 

PAMPLONA, Spain, September 30, 2010 /PRNewswire/ -- The global biotechnology industry has been more resistant to the economic crisis than expected. This has been one of the main conclusions of the international round table "Opportunities and Challenges of the Global Biomarkets", held as part of the 5th International Meeting on Biotechnology, BioSpain 2010, organised by the Spanish Association of Biocompanies (ASEBIO) and the Government of Navarre through SODENA. During this event, experts from around the world have talked about their experience of each of their geographic locations in the field of biotechnology. Among the most important issues discussed they highlighted two: the increasing selectiveness of investors and the cuts in R&D+i. An important figure that was discussed was a "modest decrease" of 10% of the number of biotechnology companies worldwide, despite the crisis. During the round table it was made clear that "financing is the main problem faced by biotechnology today".

The Minister of Science and Innovation, Cristina Garmendia, has visited BioSpain 2010 to "see how Pamplona has become the nerve centre of European biotechnology". The Minister has mentioned the support offered by the central Government. "Undoubtedly, the biotechnology sector is bound to become one of the crucial sectors involved in our economic recovery, and I think that the figures and the international interest shown are proof of this; this helps us understand that it is the way forward". Garmendia referred to the General State Budgets, presented today, which allocate over 5.35 billion euros to the Ministry of Science and Innovation, 1.2 % more than the previous year. "With this budget, which has yet to be passed through parliament, we can guarantee the financing of all the contracts, grants, research projects and transfers of research to public bodies".

The protagonist of today's plenary session was Larry Fritz, president and CEO of Covella Pharmaceuticals, who stressed that the current model of venture capital has to be revised. "Venture capital has lost its entrepreneurial mindset; today investors leave their decisions in the hands of external consultants who, in many cases, are too critical of the projects that require financing". Larry Fritz, who focused his talk on how to create and develop a successful biotechnology company, insisted that investors are more conservative and that work is done more slowly than a few years ago.

More information: Lucia Cecilia Mercado +34-91-210-93-74 lcecilia@asebio.com
'/>"/>

SOURCE Asebio
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Inc. Magazine Names Senior Whole Health the Number One Fastest-Growing Private Company in US
2. Palatin Technologies, Inc. Revised Call-In Number for Teleconference and Webcast to be held on September 30, 2008
3. Angiotech Announces Webcast and Call-in Numbers for Annual and Special General Meeting of Shareholders
4. AstraZeneca Calls on All Americans to Join US AGAINST ATHERO to Fight the Nations Number One Killer
5. A number of European companies working together to create innovative facades with nanomaterials
6. Rapid Increase in the Number of Worldwide Nanotechnology Degree Programs
7. China-Biotics Ranked Number 62 on FORTUNES 100 Fastest-Growing Companies List
8. Random numbers game with quantum dice
9. InNexus Biotechnology Announces Launch of Large Scale Primate Study of DXL625
10. Yongye Biotechnology International Retains CCG Investor Relations
11. Yongye Biotechnology International Announces Conference Call to Discuss Second Quarter 2008 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... 2016  Spherix Incorporated (Nasdaq: SPEX ) -- an intellectual ... of intellectual property, today provided an update on the ... District of Texas and announcing ... Inter Partes Re-examination ("IPR") proceedings that VTech and ... was initiated on only certain claims of two of ...
(Date:2/4/2016)... ... February 04, 2016 , ... ... leading supplier of Semantic Graph Database technology has been recognized As “ Best ... by Corporate America Magazine. , “At Corporate America, it’s our priority to showcase ...
(Date:2/4/2016)... NY (PRWEB) , ... February 04, 2016 , ... Many ... for over 10 years. What sets them apart from other cuvette manufacturers ... is posted on their website. On top of this steady flow of inside ...
(Date:2/3/2016)...  Discovery Laboratories, Inc. (NASDAQ: DSCO ), ... surfactant therapies for respiratory diseases, today announced that ... award as a component of employment compensation for ... and Chief Executive Officer.  The award was approved ... 2016 and granted as an inducement material to ...
Breaking Biology Technology:
(Date:1/15/2016)... , Jan. 15, 2016 Recent publicized breaches ... to find new ways to ensure data security and ... iOS and Android that ties a ... transforming it into a hardware authorization token. Customer service ... their fingerprint on their KodeKey enabled device to verify ...
(Date:1/11/2016)...  higi, the leading retail and omni-channel community engagement ... and mobile, today announced it has closed funding ... --> --> ... higi,s health platform – its network of health ... expanding services and programs to retail partners and ...
(Date:1/7/2016)... Jan. 7, 2016 Various factors have ... products such as biologics and biosimilars. Some of ... healthcare expenditure, growing demand for cost-effective alternatives, growing ... Biosimilars are similar versions of their corresponding patented ... their quality, safety, and efficacy. The global biosimilars ...
Breaking Biology News(10 mins):